Segmentation by type classifies the Amino Acid in Dietary Supplements market into essential amino acids (EAAs), non‑essential amino acids (NEAAs), branched‑chain amino acids (BCAAs), and conditioned amino acids. EAAs, which the human body cannot synthesize, are marketed in balanced blends to ensure complete protein synthesis; they represent roughly 35 % of total market volume due to their foundational role in muscle maintenance and recovery. NEAAs, such as glutamine and alanine, are offered for specific metabolic functions and account for about 20 % of sales, reflecting niche demand from clinical and endurance‑athlete segments. BCAAs—leucine, isoleucine, and valine—are sold as isolated or stacked products targeting rapid muscle protein synthesis; this sub‑category contributes the largest share, close to 40 %, driven by high adoption rates in sports‑nutrition formulations. Conditioned amino acids, including arginine, citrulline, and taurine, are positioned for vasodilation, cardiovascular health, and cognitive support, comprising the remaining 5 % of the market. The type‑based taxonomy clarifies product‑development pathways and aligns supply‑chain investments with the relative revenue potential of each amino‑acid class.